SCREENING FOR THROMBOPHILIA: RETROSPECTIVE STUDY IN WOMEN WITH GESTACIONAL VASCULAR COMPLICATIONS
Abstract number: P-T-597
Mariz1 M., Corbillón1 L., Abreu Lima1 J., Pereira1 M., Matos1 R., Braga2 J., Morais1 S., Campos1 M.
11Hematologia Clínica 22Obstetrícia, Hospital Geral Sto. António, Porto, Portugal
How-to-cite Mariz M, Corbillón L, Abreu Lima J, Pereira M, Matos R, Braga J, Morais S, Campos M. SCREENING FOR THROMBOPHILIA: RETROSPECTIVE STUDY IN WOMEN WITH GESTACIONAL VASCULAR COMPLICATIONS. J Thromb Haemost 2007; 5 Supplement 2: P-T-597
Abstract
Introduction: Pregnancy loss, defined as two or more spontaneous abortions, is a well-established complication of several acquired thrombophilic disorders, including the antiphospholipid syndrome and essential thrombocythemia. More recently, inherited thrombophilia has been shown to increase susceptibility to fetal loss. Emerging data also suggests that inherited thrombophilia was more common in women with gestational vascular complications.We evaluated the presence of genetic or acquired thrombophilia in 69 women with gestational vascular complications.
Methods: A total of 69 women with obstetric complications such as 1st trimester recurrent fetal loss (34), 2nd and 3rd trimester fetal loss (21) and severe pre-eclampsia/HELLP syndrome (14) were studied. These patients were tested for the presence of known genetic risk factors of thrombosis (Factor V Leiden, Prothrombin 20210 G>A, MTHFR 677 C>T, PAI-1 4G) and for the presence of alterations in the circulating levels of Protein C, Protein S, Antithrombin III, PAI, tPA, ACA-IgG, ACA-IgM, b2GPI-IgG, b2GPI-IgM and Lupus Anticoagulant. 203 healthy blood donors were used as a control population for the genetic risk factors.
Results: Anti-phospholipid antibodies were found in 7 patients (10%), 3 of them suffering from 1st trimester recurrent fetal loss, 2 from 2nd-3rd trimester fetal loss and the remainder 2 from severe pre-eclampsia/HELLP syndrome. Only 1 woman had decreased AT III levels and another patient showed increased PAI-1 levels. No patient was deficient for proteins C or S. Factor V Leiden mutation was found in 2,8% of cases, Prothrombin G20210A in 4,3% and MTHFR C677T in 60% (12% homozygous).
Conclusions: Out of anti-phospholipidic antibodies, we have found no significant thrombophilic risk factors in women with obstetric complications. The frequency of the above mentioned mutations was
similar to the frequency found on the control population. Larger studies are needed in order to evaluate the incidence of thrombophilia in women with obstetric complications.
